OTCMKTS:BSPM

Biostar Pharmaceuticals Competitors

$0.17
+0.01 (+6.25 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.17
Now: $0.17
$0.17
50-Day Range
$0.17
MA: $0.19
$0.25
52-Week Range
$0.05
Now: $0.17
$0.38
Volume195 shs
Average Volume4,940 shs
Market Capitalization$448,800.00
P/E RatioN/A
Dividend YieldN/A
Beta1.6

Competitors

Biostar Pharmaceuticals (OTCMKTS:BSPM) Vs. IMUC, CDXI, ETST, MLNTQ, AKAOQ, and AOLS

Should you be buying BSPM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Biostar Pharmaceuticals, including ImmunoCellular Therapeutics (IMUC), Cardax (CDXI), Earth Science Tech (ETST), Melinta Therapeutics (MLNTQ), Achaogen (AKAOQ), and Aeolus Pharmaceuticals (AOLS).

ImmunoCellular Therapeutics (OTCMKTS:IMUC) and Biostar Pharmaceuticals (OTCMKTS:BSPM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares ImmunoCellular Therapeutics and Biostar Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoCellular TherapeuticsN/AN/AN/AN/AN/A
Biostar PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for ImmunoCellular Therapeutics and Biostar Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoCellular Therapeutics0000N/A
Biostar Pharmaceuticals0000N/A

Profitability

This table compares ImmunoCellular Therapeutics and Biostar Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoCellular TherapeuticsN/AN/AN/A
Biostar PharmaceuticalsN/AN/AN/A

Volatility & Risk

ImmunoCellular Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Biostar Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Biostar Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Cardax (OTCMKTS:CDXI) and Biostar Pharmaceuticals (OTCMKTS:BSPM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Institutional & Insider Ownership

8.7% of Cardax shares are owned by institutional investors. 17.2% of Biostar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Cardax and Biostar Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardax$710,000.002.35$-5,090,000.00N/AN/A
Biostar PharmaceuticalsN/AN/AN/AN/AN/A

Biostar Pharmaceuticals has lower revenue, but higher earnings than Cardax.

Analyst Ratings

This is a summary of current ratings and price targets for Cardax and Biostar Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardax0000N/A
Biostar Pharmaceuticals0000N/A

Profitability

This table compares Cardax and Biostar Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardax-891.77%N/A-297.64%
Biostar PharmaceuticalsN/AN/AN/A

Volatility & Risk

Cardax has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Biostar Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Summary

Biostar Pharmaceuticals beats Cardax on 4 of the 6 factors compared between the two stocks.

Earth Science Tech (OTCMKTS:ETST) and Biostar Pharmaceuticals (OTCMKTS:BSPM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Earnings & Valuation

This table compares Earth Science Tech and Biostar Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Earth Science Tech$530,000.002.76$-1,200,000.00N/AN/A
Biostar PharmaceuticalsN/AN/AN/AN/AN/A

Biostar Pharmaceuticals has lower revenue, but higher earnings than Earth Science Tech.

Profitability

This table compares Earth Science Tech and Biostar Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Earth Science Tech-1,750.31%N/A-2,929.76%
Biostar PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Earth Science Tech and Biostar Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Earth Science Tech0000N/A
Biostar Pharmaceuticals0000N/A

Volatility and Risk

Earth Science Tech has a beta of 2.53, indicating that its stock price is 153% more volatile than the S&P 500. Comparatively, Biostar Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Biostar Pharmaceuticals (OTCMKTS:BSPM) and Melinta Therapeutics (OTCMKTS:MLNTQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Biostar Pharmaceuticals and Melinta Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biostar Pharmaceuticals0000N/A
Melinta Therapeutics0000N/A

Earnings and Valuation

This table compares Biostar Pharmaceuticals and Melinta Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biostar PharmaceuticalsN/AN/AN/AN/AN/A
Melinta Therapeutics$96.43 million0.02$-157,190,000.00N/AN/A

Biostar Pharmaceuticals has higher earnings, but lower revenue than Melinta Therapeutics.

Profitability

This table compares Biostar Pharmaceuticals and Melinta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biostar PharmaceuticalsN/AN/AN/A
Melinta TherapeuticsN/AN/AN/A

Summary

Melinta Therapeutics beats Biostar Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Biostar Pharmaceuticals (OTCMKTS:BSPM) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Biostar Pharmaceuticals and Achaogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biostar Pharmaceuticals0000N/A
Achaogen0000N/A

Earnings and Valuation

This table compares Biostar Pharmaceuticals and Achaogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biostar PharmaceuticalsN/AN/AN/AN/AN/A
Achaogen$8.73 million0.14$-186,510,000.00N/AN/A

Biostar Pharmaceuticals has higher earnings, but lower revenue than Achaogen.

Volatility and Risk

Biostar Pharmaceuticals has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

Profitability

This table compares Biostar Pharmaceuticals and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biostar PharmaceuticalsN/AN/AN/A
AchaogenN/AN/AN/A

Institutional & Insider Ownership

0.0% of Achaogen shares are held by institutional investors. 17.2% of Biostar Pharmaceuticals shares are held by company insiders. Comparatively, 7.8% of Achaogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biostar Pharmaceuticals (OTCMKTS:BSPM) and Aeolus Pharmaceuticals (OTCMKTS:AOLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Biostar Pharmaceuticals and Aeolus Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biostar PharmaceuticalsN/AN/AN/AN/AN/A
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Biostar Pharmaceuticals and Aeolus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biostar PharmaceuticalsN/AN/AN/A
Aeolus PharmaceuticalsN/AN/AN/A

Risk and Volatility

Biostar Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Aeolus Pharmaceuticals has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Biostar Pharmaceuticals and Aeolus Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biostar Pharmaceuticals0000N/A
Aeolus Pharmaceuticals0000N/A

Summary

Aeolus Pharmaceuticals beats Biostar Pharmaceuticals on 1 of the 1 factors compared between the two stocks.


Biostar Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51+2.0%$1.80 millionN/A0.00Gap Down
Cardax logo
CDXI
Cardax
0.0$2.10+0.0%$1.67 million$710,000.000.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03+13.7%$1.54 million$530,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11+0.0%$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03+0.0%$1.25 million$8.73 million0.00Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01+0.0%$1.19 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05+0.0%$1.12 millionN/A-0.57Upcoming Earnings
Decrease in Short Interest
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.05+0.0%$1.12 millionN/A0.00Gap Up
ATRX
Adhera Therapeutics
0.0$0.08+13.3%$1.11 million$250,000.000.00High Trading Volume
Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.23+4.4%$1.05 millionN/A0.00Decrease in Short Interest
AOXG
Aoxing Pharmaceutical
0.5$0.01+1.4%$1.05 millionN/A0.00
SPHS
Sophiris Bio
0.1$0.03+0.0%$995,000.00N/A0.00Increase in Short Interest
Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07+0.0%$970,000.00N/A0.00Increase in Short Interest
Gap Up
PXYN
Praxsyn
0.6$0.00+25.0%$848,000.00N/A0.00Increase in Short Interest
STLT
Spotlight Innovation
0.5$0.02+0.0%$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03+1.6%$771,000.00N/A0.00Gap Down
SKVI
Skinvisible
0.7$0.15+0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05+0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.08+6.3%$454,000.00N/A0.00High Trading Volume
Gap Down
HSTC
HST Global
0.8$0.07+0.0%$378,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47+3.7%$338,000.00$36.55 million0.00Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01+0.0%$295,000.00N/A0.00High Trading Volume
Increase in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60+7.5%$207,000.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.07+0.0%$124,000.00N/A0.00
MetaStat logo
MTST
MetaStat
0.0$0.02+0.0%$118,000.00$20,000.000.00
PZRXQ
PhaseRx
0.2$0.03+63.9%$108,000.00N/A0.00Decrease in Short Interest
Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01+26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00+0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00+0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00+0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02+0.0%$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.05+22.2%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.08+12.5%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50+0.0%$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.02+0.0%$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01+0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08+12.7%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01+0.0%$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49+0.0%$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04+0.0%$0.00N/A0.00News Coverage
FTCY
Global Future City
0.5$0.00+0.0%$0.00N/A0.00
GLSI
Greenwich LifeSciences
1.7$39.15+36.9%$0.00N/A0.00High Trading Volume
Decrease in Short Interest
News Coverage
Gap Up
HRBR
Harbor Diversified
0.0$1.18+5.1%$0.00$263.61 million0.00Gap Down
IPAH
Interpharm
0.2$0.00+0.0%$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00+0.0%$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02+8.7%$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.05+5.8%$0.00N/A0.00Decrease in Short Interest
Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00+0.0%$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.07+0.0%$0.00N/A0.00
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.